Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Drug-Related Side Effects and Adverse Reactions 2Breast Neoplasms 2Sarcoma, Alveolar Soft Part 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Ovarian Neoplasms 1Lymphoma, Non-Hodgkin 1Lymphoma 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1Carcinoma, Ovarian Epithelial 1Carcinoma, Non-Small-Cell Lung 1Cancer Related Fatigue 1Breast Neoplasms, Male 1

Interventions

Rituximab 205Cyclophosphamide 178Peripheral Blood Stem Cell Transplantation 93Etoposide 91fludarabine phosphate 86Filgrastim 81Melphalan 62Vincristine 60Mycophenolic Acid 58Busulfan 58Whole-Body Irradiation 57Cytarabine 51Radiotherapy 49Doxorubicin 49Cyclosporine 49Tacrolimus 48Granulocyte Colony-Stimulating Factor 48Prednisone 46fludarabine 45Bendamustine Hydrochloride 45Methotrexate 44Carmustine 36Antilymphocyte Serum 34Dexamethasone 32Bortezomib 29Gemcitabine 27ibritumomab tiuxetan 25Methylprednisolone 23sargramostim 22Stem Cell Transplantation 22

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Lymphoma, Non-Hodgkin × Pyridoxine × Clear all
NCT01983969 2020-01-27

Aza-SAHA-GBM With AutoSCT for Refractory Lymphoma

M.D. Anderson Cancer Center

Phase 1/2 Completed
61 enrolled 10 charts
Lymphoid

Lymphoma, Lymphoma, Non-Hodgkin

Data powered by HemOnc (CC BY 4.0) Colophon âš¡